Madopar Depot (Benserazide Hydrochloride, Levodopa)

Madopar Depot is used within the dopaminergic pathway to manage motor symptoms of Parkinsonian disorders.

• Parkinson's disease: improves tremor, rigidity, and bradykinesia in patients.
• Parkinsonian syndrome: reduces motor fluctuations and enhances functional mobility.
• Levodopa‑responsive Parkinsonism: restores dopamine levels to alleviate symptoms in responsive cases.

• Madopar Depot combines levodopa, a dopamine precursor, with benserazide, a peripheral aromatic L‑amino acid decarboxylase inhibitor. Benserazide blocks peripheral conversion of levodopa, allowing a greater proportion to cross the blood‑brain barrier. Inside the CNS, levodopa is decarboxylated to dopamine, replenishing depleted dopaminergic neurotransmission and improving motor control in Parkinsonian patients.

Adverse reactions to Madopar Depot vary in frequency and severity.

Common Side Effects

• Nausea: feeling of stomach upset, often occurring after dose initiation.
• Dizziness: light‑headed sensation, especially when standing quickly.
• Headache: mild to moderate cranial pain.
• Orthostatic hypotension: drop in blood pressure upon standing.

Serious or Rare Side Effects

• Dyskinesia: involuntary, erratic movements that may affect daily activities.
• Hallucinations: visual or auditory disturbances, particularly in older patients.
• Severe hypotension: marked blood pressure fall requiring medical attention.
• Neuroleptic malignant syndrome: rare but life‑threatening reaction with fever and muscle rigidity.

Before prescribing Madopar Depot, clinicians should consider several precautionary measures to ensure safe use.

• Dose titration: start low and increase gradually to minimize adverse effects.
• Blood pressure monitoring: watch for orthostatic hypotension, especially in the elderly.
• Renal and hepatic function: assess organ status and adjust dosing if impairment is present.
• Discontinuation: avoid abrupt cessation to prevent withdrawal symptoms.
• Pregnancy and lactation: use only if potential benefit justifies potential risk to fetus or infant.
• Store at ambient temperature below 25°C: keep in the original container, protect from moisture and light.

Madopar Depot may interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• Non‑selective MAO inhibitors (e.g., phenelzine): risk of hypertensive crisis.
• Antipsychotics (e.g., haloperidol, chlorpromazine): may diminish antiparkinson effect.
• Iron or calcium supplements: reduce levodopa absorption when taken concurrently.
• High‑protein meals: compete with levodopa transport across the gut.
• COMT inhibitors not co‑prescribed: can cause excessive levodopa levels.

Moderate Interactions (Monitor Closely)

• Selective MAO‑B inhibitors (e.g., selegiline, rasagiline): may increase dopaminergic activity.
• Antihypertensive agents: additive effect on blood pressure lowering.
• SSRIs or SNRIs: potential for serotonin syndrome when combined with levodopa.
• Diuretics: may enhance orthostatic hypotension.
• Alcohol: can exacerbate dizziness and hypotension.